



Investor Service Announcement no.7/2008

To: NASDAQ OMX Copenhagen

Hørsholm, Denmark, November 20, 2008

**LifeCycle Pharma A/S to Host Conference Call Announcing  
Interim Results for the Third Quarter of 2008**

LifeCycle Pharma A/S (OMX: LCP) will announce interim results for the third quarter of 2008 (January 1 – September 30) on Thursday, November 27, 2008. The results will be announced before the opening of Nasdaq OMX Nordic Exchange Copenhagen. LCP's Executive Management will host an accompanying conference call to discuss the financial results on Thursday, November 27, 2008, at 15:00 CET (Denmark); 14:00 GMT (London); 09:00 AM ET (New York); 06:00 AM PT (San Francisco).

To access the live conference call, please dial one of the following numbers:

+1 866 966 5335 (US)

+44 2030 032 666 (UK)

+45 8088 8649 (DK)

An audio replay of the conference call will be available on [www.lcpharma.com](http://www.lcpharma.com) from Friday, November 28, 2008, at 16:00 CET (Denmark); 15:00 GMT (London); 10:00 AM ET (New York); 07:00 AM PT (San Francisco), through Friday, December 26, 2008, by dialing +44 2081 961 998 (UK) or +1 866 583 1035 (US), and entering access code 8403 264#.

**For more information, please contact:**

Dr. Jim New

President & CEO

Phone: +45 7033 3300

[JSN@lcpharma.com](mailto:JSN@lcpharma.com)

**About LifeCycle Pharma A/S ("LCP"):** LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, Fenoglide™, currently on the US market and a diversified near- and medium-term pipeline, including four product candidates in clinical trials and two in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit [www.lcpharma.com](http://www.lcpharma.com)